Akira Yokota

Chiba, JP 
Chiba, JP 

Overview

Akira Yokota practices practicing medicine in Chiba, Japan.

Their clinical expertise encompasses Hypereosinophilic Syndrome, Hepatic Venoocclusive Disease with Immunodeficiency, Myelodysplastic Syndrome (MDS), Leukemia, and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 70 peer reviewed articles and participating in 1 clinical trial.

Locations

Chiba, Japan
Other Locations
Gifu-shi, Japan
Tsu, 5148507, Japan
Aoba, Japan
Chuo, 2600852, Japan
Shibata Gun, 9891311, Japan
Sendai, 9800845, Japan
Yayoi, 1130032, Japan
Tokyo, Japan
Kyoto, Japan
Kashiwa, 2778564, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Study Phase: Phase 3

70 Total Publications

Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.
Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.
Journal: Nature medicine
Published: May 05, 2026

Frequently Asked Questions about Akira Yokota

Is Akira Yokota a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Akira Yokota is classified as an Experienced expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Akira Yokota participate in research or clinical trials?

Yes. Akira Yokota has published 70 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Akira Yokota's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yokota's expertise for a condition
ConditionClose
        View All 12 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile